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Recently, eight allelic variants of the pertactin gene ( prn1-8) have been
characterized in Bordetella pertussis strains isolated in Europe and the
United States. It has been suggested that the divergence of the pertactin
types of clinical isolates from those of the B. pertussis vaccine strains is a
result of vaccine-driven evolution. Sequencing of the prn, which is relatively
time-consuming, has so far been the only method for the differentiation of
prn types. We have developed a rapid real-time polymerase chain reaction
assay suitable for large-scale screening of the prn type of the circulating
strains. This method correctly identified the prn type of all tested 41 clinical
isolates and two Finnish vaccine strains. The method is simple and reliable
and provides an alternative for sequencing in pertussis research.
Bordetella pertussis is the causative agent of pertussis
(whooping cough), which is increasing in incidence in several
countries despite high vaccination rates (1-5). One explana-
tion for the increase might be the adaptation of B. pertussis
bacteria to vaccine-induced immunity. Pertactin, a 69-kDa
outer membrane protein, is an important virulence factor of
B. pertussis. Because pertactin elicits protective immunity in
animals and humans during vaccination (6-9), this protein is
included in most new acellular pertussis vaccines. Pertactin
contains two immunodominant regions, regions 1 and 2,
comprising repeating units of five (GGxxP) or three (PQP)
amino acids, respectively (10-12). It has been suggested that
the number of the units is regulated through genetic recom-
bination (12). Recently, eight allelic variants of the pertactin
gene (prn1-8) have been characterized in B. pertussis strains
isolated in Europe and the United States (12-16). Most of the
allelic variation in prn1-5 are restricted to region 1, whereas
prn6-8 also show variation in region 2 (13). prn1-3 are the
predominant types, representing >90% of tested clinical iso-
lates (12-16), whereas vaccine strains have exclusively prn1
(12,14-16). Of 92 strains isolated between 1989 and 1999 in
the United States, 30% harbored prn1 and 70% prn2 (14). In
the Netherlands and Finland, approximately 10% of clinical
strains isolated in the 1990s harbored prn1 and 90%, prn2 or
prn3 (12,15).
So far, the only means of determining the pertactin type
has been polymerase chain reaction (PCR)-based sequencing
of the prn gene, a relatively time-consuming and expensive
method. To monitor the variation of clinical isolates on a
large scale, a rapid and simple method is needed. The recent
applications of fluorescence techniques to PCR allow real-
time monitoring of accumulation of the amplified product
and accurate analysis of the melting temperatures of either
the amplified product itself or the attached hybridization
probes (17-21). In the hybridization probe format the two
independent, nonextendible, single-labeled oligonucleotide
probes hybridize adjacently on the amplicon internal to the
flanking PCR primers. After excitation by the light-emitting
diode, a fluorescence resonance energy transfer (FRET)
occurs from the donor dye to the acceptor dye, increasing the
signal emitted by the acceptor dye (22).  
We developed a simple method to characterize the
pertactin variants (Figure 1). The strains with the frequent
types, prn1-5, were first differentiated from strains with the
rare types, prn6-8, by a real-time allele-specific amplification
(ASA) assay. Strains representing prn1-5 were further iden-
tified by a real-time PCR combined with the melting curve
analysis of FRET probes and gel electrophoresis. Results
were compared to those obtained by sequencing (15). The
speed and simplicity of this approach make it an advanta-
geous alternative to conventional sequencing of the prn gene.
Materials and Methods
Bacterial Strains and DNA Sequencing
Forty-one clinical  B. pertussis isolates and 2 Finnish
vaccine strains were selected from the strain collection of the
Pertussis Reference Laboratory, National Public Health
Institute, Turku, Finland. All 41 clinical isolates originated
from Finland and were isolated from 1956 to 1996. The prn
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genes of these isolates and strains have been previously
sequenced, and the  prn sequences of 38 were published
earlier (15). All the Finnish strains represented  prn1-4.
Strains B935 (AJ011016), 18323 (AJ132095), B567
(AJ133784), and B1092 (AJ133245) harbor prn5, prn6, prn7,
and prn8, respectively.
Bacteria were cultivated on Regan-Lowe medium con-
taining charcoal agar and defibrinated horse blood at 35°C
for 3 days (23). Bacterial colonies on the plates were har-
vested for isolation of DNA. PCR-based sequencing was done
as described previously (12).
Primers and Probes
Primers for real-time ASA and the FRET probe assay
were designed on the basis of the published sequence of the
prn genes (10,12,15,16) and synthesized at Eurogentech,
Seraing, Belgium (Table 1). Of primers used in ASA assay
(Table 1) (Figures 2,3), QJF3 contained a specific mismatch
G at the 3' end that did not complement the published
sequences of any prn type. The T (boldfaced) at the 3'end of
QJF3 (corresponding to the nucleotide 1595) was comple-
mentary to prn1-5 but not to prn6-8 to permit preferential
amplification of the former types. The two mismatches at the
3'end of QJF3 would guarantee the absence of PCR amplifi-
cation when the sequences of  prn6-8 are used as targets
(24,25). The primers QJF3 and QJR1 define a 72-bp long
PCR product. The primers QH8F' and QH2R used in the
FRET probe assay define a 260-bp long PCR product. Based
on earlier sequencing data, the calculated lengths of the PCR
products were 260 bp, 275 bp, 260 bp, 245 bp, and 245 bp for
prn1,  2, 3, 4, and  5, respectively. The FRET hybridization
probes QJ1 and QJ2 were designed on the basis of the
sequence of prn1 to differentiate prn1 from prn3 (Table 1)
(Figures 3,4). The boldfaced T of probe QJ2 is complemen-
tary to C to T transition specific for prn1 (corresponding to
nucleotide 828) (13). Binding of probe QJ2 to prn5 (compared
to the  prn1-4) will be hampered since no complementary
sequence to the probe is available on  prn5 (Figure 4A, B).
Probes were synthesized at TIB Molbiol, Berlin, Germany.
QJ1 (used as the donor probe in FRET technology) was
labeled with fluorescein at the 3' end. QJ2 was labeled with
LightCycler Red 640 at the 5'end and phosphorylated at the
3' end; this was used as the acceptor probe in the FRET
(Table 1) (Figure 4A).
DNA Preparation 
DNA was extracted from bacterial colonies by using the
DNA Isolation Kit for Blood/Bone Marrow/Tissue (Roche
Diagnostics, Mannheim, Germany) according to the
Figure 1. Workflow for typing prn alleles. The allele-specific amplifi-
cation (ASA) assay (step number 3) and the fluorescence resonance
energy transfer (FRET) probe assay (step number 4) each require
approximately 1 hour. 






QJF3c GCT GGT GCA GAC GCC AGT 1578-
1595
QJR1c  CCG ATA TCG ACC TTG CC 1649-
1633
QH8Fd CTG CAG CGC GCG ACG ATA 757-
774 
QH2Rd  ATT GCC GTG CGG TGC GGA CAA 1026-
1006
QJ1e  CCG GCG GTG CGG TTC C-F 809-
824
QJ2e  LC Red 640-CGG TGG TGC GGT TCC C-P 825-
840
aModifications of primer or probe are boldfaced or underlined.
bPosition numbers indicate the position of bases relative to the first start
codon of prn1.
cPrimers used in the real-time allele-specific amplification. QJF3
contained a specific mismatch G (underlined) at the 3' end that does not
complement the published sequences of any prn type. The T (boldfaced) at
the 3' end (corresponding to the nucleotide 1595) is complementary to
prn1-5. Primer QJF3 has two mismatches with prn6-8. 
dPrimers used in fluorescence resonance energy transfer (FRET) probe
assay.
eProbes used in FRET probe assay. Boldfaced T is complementary to C to T
transition specific for prn1. QJ1 was labeled with fluorescein at the 3' end
and QJ2 with LC Red at 5' end and phosphorylated at the 3' end.
Figure 2. Partial sequence of the  prn gene of Bordetella pertussis,
showing the position of QJF3 primer. Consensus bases are shown
with dashes, and the mismatched bases in the primer are under-
lined.
Figure 3. Schematic structure of the prn1  gene, showing the position
of the primers used in the allele-specific amplification assay (1.),
and the primers and probes used in the fluorescence resonance
energy transfer probe assay (2). Proportions of the gene are not
drawn to scale. F = fluorescein; LC = LC red 640; and P = phosphate.Research
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manufacturer's instructions. Extracted DNA concentrations
were measured with a GeneQuant spectrophotometer (Phar-
macia Biotech, NJ, USA). DNA concentrations in all samples
were adjusted to 3 ng/µL. DNA preparations were stored at
-20°C.
Allele-Specific Amplification (ASA) 
ASA PCR, which distinguishes between  prn1-5 and
prn6-8, was performed in a fluorescence temperature cycler
(LightCycler, Roche). The PCR reaction mixture was opti-
mized for the LightCycler and amplified according to the
manufacturer’s protocol. The final volume of 20 µL contained
2 µL of LightCycler-DNA Master SYBR Green I (containing
Taq DNA polymerase, reaction buffer, deoxynucleoside triph-
osphate (dNTP) mix and dsDNA binding dye SYBR Green I),
4 mM MgCl2 (Roche), 8 pmol of the primers QJF3 and QJR1,
5% dimethyl sulfoxide (Merck, Darmstadt, Germany), and 2
µL of 3-ng/µL sample DNA. A negative control without DNA
and a positive control that contained 6 ng of the DNA from
strain 1772 (prn1) were included in each run. The amplifica-
tion protocol consisted of the initial denaturation step at 94°C
for 30 seconds, 30 cycles of denaturation at 95°C for 1 second,
annealing at 62°C for 5 seconds, and extension at 72°C for 4
seconds. The temperature transition rate was 20°C per sec-
ond. Fluorescence was measured at the end of each extension
step at 530 nm. The increase in the fluorescence signal corre-
lates to the accumulation of PCR product (19,22).
After amplification, melting curve analysis of the PCR
product was used to differentiate between specific and non-
specific amplification products. Melting curve was acquired
by heating the product at 20°C/seconds to 95°C, cooling it at
20°C/seconds to 55°C for 30 seconds, and slowly heating it at
0.1°C/seconds to 94°C under continuous fluorescence moni-
toring. Melting curve analysis was accomplished with Light-
Cycler software. As the temperature reaches the specific Tm
of the PCR product, the double-stranded product is rendered
into the single-stranded form. A rapid loss of fluorescence
can be observed as the double-stranded DNA binding dye
SYBR green I detaches from the PCR products. The change
in fluorescence signal intensity is then plotted as the nega-
tive derivative of fluorescence versus temperature (–dF/dT
vs T graphs) to obtain the characteristic melting peaks. In
constant reaction conditions (salt concentration and the
like), the position of the melting curve peak (Tm) is a func-
tion of the GC/AT ratio, length, and nucleotide sequence of
the PCR product (26). Melting curve analysis has been suc-
cessfully used in the differentiation of PCR products with a
difference of even <2°C in the Tm (18,26).
Hybridization Probe Assay
The hybridization probe assay was carried out by using
the FRET probe format of LightCycler. The PCR reaction
mixture was optimized for the LightCycler and amplified
according to the manufacturer’s protocol. The final volume of
20 µL contained 2 µL of LightCycler-DNA Master Hybridiza-
tion Probes (containing Taq DNA polymerase, reaction
buffer, and dNTP mix), 3 mM MgCl2 (Roche), 1.5 pmol of the
FRET probes QJ1 and QJ2, 8 pmol of the primers QH8F' and
QH2R, 220 ng of TaqStart antibody (ClonTech, CA, USA),
10% dimethyl sulfoxide (Merck), and 2 µL of sample DNA. A
negative control without DNA and two positive controls rep-
resenting prn1 and 3 were included in each run. The temper-
ature profile of the real-time PCR included an initial
denaturation step at 94°C for 120 seconds followed by 40
cycles of denaturation at 94°C for 2 seconds, annealing at
55°C for 10 seconds, and extension at 72°C for 12 seconds.
The temperature transition rate was 20°C/s. Fluorescence
was measured at 640 nm at the end of the annealing step of
each cycle to monitor the accumulation of PCR product.
After amplification, a melting curve was acquired by
heating the product at 20°C/seconds to 95°C, cooling it at
20°C/seconds to 42°C for 120 seconds, and slowly heating it
at 0.1°C/seconds to 80°C under continuous fluorescence mon-
itoring. Melting curve analysis was accomplished using
LightCycler software. In the hybridization probe format, the
rapid loss of fluorescence is observed when the temperature
Figure 4A. Nucleotide sequences of polymorphic regions of different types of the prn gene and the sequences of the fluorescence resonance
energy transfer probes aligned to their hybridization positions in the prn gene. Number 790 refers to the position of bases relative to the first
start codon of prn1. Underlined regions represent repeats in the sequence. B. Amino acid sequences of polymorphic regions of different pert-
actin types. Dashes indicate caps in the sequence.Research
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reaches the Tm of the probes. The two adjacently bound
probes dissociate from their complementary target, which
prevents the fluorescence resonance energy transfer. Melt-
ing curve analysis allowed us to discriminate the specific
binding of the hybridization probes to the amplified segment
of the prn1 from their less specific binding to the amplified
segments of the other prn types. 
Analysis of the FRET Hybridization Probe
Assay PCR Products by Gel Electrophoresis
A 20-µL volume of LightCycler PCR product from the
hybridization probe assay was removed from the capillary by
removing the cap, placing the capillary upside down in an
empty Eppendorf tube, and centrifuging for 5 seconds. A 10-
µL volume of the PCR product was run (100 V for 3 hours) in
a 3% molecular screening (MS) agarose gel (Roche Diagnos-
tics) together with a 100-bp DNA ladder (Amersham).
According to the manufacturer, the resolution characteris-
tics of MS agarose enable separation of fragments that differ
in size by as little as 4 bp. After being stained with ethidium
bromide, the bands in the gel were visualized and photo-
graphed under UV light. To avoid PCR contamination, three
separate rooms were used for preparing the PCR mixtures,
performing PCR reactions, and analyzing PCR products.
Statistical Analysis 
The Student t test was used to analyze statistical signif-
icance. All p values corresponded to two-tailed tests, and p
<0.05 was considered significant.
Results
Differentiation of prn1-5 from 6-8 
The ASA assay was used as a screening method to  dif-
ferentiate the frequent  prn types (prn1-5) from rare types
(prn6-8). When compared to previous sequencing data (12),
all type strains and clinical isolates were correctly catego-
rized by this assay. The mean Tm  of the PCR products
derived from the prn1-5 strains was 83.4°C (standard devia-
tion [SD] 0,54) (Figure 5). There was no specific amplifica-
tion from the strains with prn6-8. The nonspecific products,
such as primer dimers, melt below 80°C and were differenti-
ated from the specific products by the melting curve analy-
sis. These results were also confirmed by gel electrophoresis.
Melting Curve Analysis of Hybridization Probe Assay
Strains that were found to harbor prn1-5 in the screen-
ing were further analyzed by the combination of hybridiza-
tion probe assay and gel electrophoresis. FRET probes were
designed as complementary to the prn1 gene. The Tms and
results of the melting curve analyses of the strains with the
prn1 gene differed markedly from those of strains with prn2,
prn3, and  prn4 (Figure 6). All nine strains harboring the
prn1 gene showed an abrupt decrease in the fluorescence sig-
nal (Table 2) and a melting peak (Figure 6) at 58.78°C (SD
0.26). The corresponding melting peak was observed at the
same temperature in all nine prn1 strains. Although probes
did not remain bound to PCR products of  prn2, prn3, and
prn4 when the fluorescence signal was measured at the end
of the annealing cycle at 55°C, probes bound to those prod-
ucts at the beginning of the melting analysis at 42°C, and
Tm and the area under the melting curve (AUC) could also
be determined for these products. As expected, the Tm of
FRET probes bound to the PCR products derived from prn2,
prn3, and  prn4 was 2°C lower (56.49°C) than that of the
FRET probes bound to the PCR product of prn1 (all p values
for differences between the Tm of prn1 and that of the other
prn types were <0.0001) (Table 2) (Figure 6). The AUC of the
hybridization probe melting curve of  prn1 was approxi-
mately 20 times larger than that of the melting curve of the
prn2, prn3, and prn4 (all p values <0.0001) (Table 2) (Figure
6). There was no detectable binding of FRET probes to the
PCR products derived from the prn5 strain (Figure 6). DNA
isolated from the strain with prn5 (together with DNAs from
strains representing  prn1-4 that served as controls) was
tested in triplicate and with different DNA concentrations
with the same result. In contrast to  prn2-4, there was no
measurable melting temperature and no AUC from the DNA
isolated from the strain with prn5, although the PCR prod-
uct was seen (245-bp long on the electrophoresis gel) (Figure
Figure 5A. Melting curves from the allele-specific amplification
assay, showing the presence of amplified products from prn1-5 and
the absence of amplification from prn6 -8 and the negative control. B.
Corresponding melting peaks derived from the melting curve. Prn1
represents the prn1-5 types; prn7 represents prn6-8 types and the
negative control. 
Figure 6. Curves showing the dissociation of fluorescence resonance
energy transfer probe assay probes from the polymerase chain reac-
tion products of different  prn types. Negative control includes all
reagents but no template DNA.
A
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7). In this setting, therefore, a sample that remained totally
negative (no measurable melting temperature and no AUC)
in the hybridization probe assay but was characterized as
prn1-5 type strain by the ASA assay was considered to
harbor prn5. 
Gel Electrophoresis of PCR Products 
Calculated sizes of PCR products were 260 bp, 275 bp,
260 bp, 245 bp, and 245 bp for prn1 to 5, respectively. PCR
products of the different prn types behaved in gel electro-
phoresis as expected on the basis of their calculated sizes
(Figure 7). Thus, prn2, prn3, and prn4 could be easily differ-
entiated by gel electrophoresis when the prn1 and prn5 were
identified by the melting curve analysis of hybridization
probes.
Identification of the prn Type of B. pertussis
Isolates and Vaccine Strains
The prn types of all tested 41 Finnish clinical B. pertus-
sis isolates and 2 Finnish vaccine strains were identified cor-
rectly when compared to types defined by sequencing (Table
2). None of these strains was found to harbor prn5-8.
Discussion
Real-time PCR combined with melting curve analysis of
FRET probes and gel electrophoresis of PCR products proved
to be an alternative to sequencing in the determination of
the pertactin gene types of B. pertussis. The method was reli-
able and accurate, as evidenced by the correct identification
of the prn type of all tested 41 clinical B. pertussis isolates,
two vaccine strains, and the four reference strains. The
advantage of this approach over sequencing is that the whole
procedure from nucleic acid extraction to gel electrophoresis
can be completed within 1 day. The disadvantages of the
method are that the novel genotypes can be missed and the
method does not differentiate prn6-8 from each other.
The low intra- and inter-assay variation coefficients of
melting temperatures show that the technical principles of
LightCycler allow consistent temperature and fluorescence
measurement conditions for the reaction capillaries. This is
a definite advantage over the corresponding instruments
using the microwell plate format, which requires intrinsic
correction to compensate for technical variation between
reaction wells.
In this study, a real-time ASA assay was used as a
screening method to first differentiate the frequent prn types
prn1-5 from the rare types prn6-8 (13). In ASA assay, when
primers designed to be specific for either wild-type or the
mutant allele are used, results depend on the presence or
absence of amplification. In this study the PCR amplification
by the primers specifically designed for the allele prn1-5 took
place with DNAs extracted from prn1-5 strains but not with
those isolated from strains representing prn6-8. When ASA
reactions occur in a fluorescence thermal cycler such as
LightCycler, accumulation of the PCR product can be moni-
tored in real-time. The analysis of specific melting
temperatures further confirms the identity of the amplified
products.
The FRET probes were specifically designed to identify
prn1 so that the strains representing the vaccine type prn
could be rapidly detected. The FRET probes also enabled dif-
ferentiation of prn1 from prn3, the two prn types that cannot
be differentiated on the basis of the size of the PCR product.
The prn1 sequence contains an additional C to T transition
(corresponding to nucleotide 828) that makes it possible to
design probes that are specific for just one  prn type. The
probes did not bind to the PCR products of prn2, prn3, prn4,
and prn5 in the fluorescence measurement phase of the PCR
cycle at 55°C. Therefore, no signal was obtained in the real-
time PCR from DNA of bacteria having these  prn types.
However, probes did bind to the PCR products of  prn2,  3,
Table 2. Comparison of the results from sequencing and the
hybridization probe assay in the determination of the pertactin gene







isolates Mean SD Area SD
1 9 58.78b  0.26 21.64b 5.64
2 25 56.31 0.44 1.25 0.30
3 4 56.59 0.09  1.35  0.26
4 5 56.57  0.29 1.43  0.25
5 1 - - - -
aAllele type determined by sequencing.  Of the strains representing
prn1-4, 41 were Finnish clinical isolates, and 2 were Finnish vaccine
strains.
bAll P values were <0.0001 when  prn1 was compared to  prn2,  prn3, or
prn4.
Figure 7. Ethidium bromide stained 3% molecular screening agarose
gel containing  Bordetella pertussis DNA amplified with primers
QH8F' and QH2R. Lanes: 1, negative control including all reagents
but no template DNA; 2, 100-bp ladder; 3, B.  pertussis strain 1772 of
type  prn1 (260 bp); 4,  Bordetella pertussis clinical isolate of type
prn2 (275 bp); 5, B. pertussis clinical isolate of type prn3  (260 bp); 6,
B. pertussis clinical isolate of type prn4 (245 bp); and 7, B. pertussis
type prn5  (245 bp).Research
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and 4 at the beginning of the melting analysis at 42°C, and
the Tm and AUC values could also be determined for these
products. Their Tm was >2°C lower and AUC approximately
20 times smaller than those of the PCR product of  prn1.
These differences clearly reflect the lower sequence compati-
bility of the probes for prn2, prn3, and prn4 than for prn1. As
expected, the Tms of prn2, prn3, and prn4 were almost iden-
tical because the target sequences of the probes in these prn
types were the same. Prn5 has the same number of repeats
as prn4 does, which makes their PCR products the same
length. However, the difference between these two is that
prn4 has two repeats of “GGAVP,” as do  prn2  and prn3,
whereas prn5 has only one such repeat. Prn5 is the only type
to which there was no detectable binding of the FRET probes
during the amplification phase or the melting curve analy-
sis. This property could be used to differentiate  prn5 from
prn4.
The difference in size of the PCR products derived from
the prn2, prn3, and prn4 (or prn5) is 15 bp. To assure the
correct identification of the pertactin types, a gel with a
high-resolution power is needed for the electrophoresis. In
this study molecular screening agarose gel was used, since
the resolution characteristics of this agarose enable
separation of fragments that differ in size by as little as 4 bp. 
Recent data suggest that B. pertussis strains having dif-
ferent prn types are circulating in Europe and the United
States. The predominant types representing >90% of the
tested clinical isolates are prn1-3 (12-16). 
In the United States, all strains isolated before 1974
harbored prn1 (14), the prn type of the strains included in
conventional whole-cell vaccines and in the new acellular
vaccines. However, nonvaccine prn types gradually replaced
the vaccine types in later years, and approximately 30% of
strains isolated between 1989 and 1999 were prn1. Similar
trends of frequency in strain types were also seen in Euro-
pean countries. The method described here is suitable for
monitoring the frequency of the strain types of clinical iso-
lates. The strains representing prn1 can be detected by run-
ning the two PCR reactions (ASA and hybridization probe
assay), and the results can be obtained within 2 hours. When
the strains that do not represent vaccine strain type need to
be clarified, gel electrophoresis of PCR products can be per-
formed. To combat pertussis and to design more effective
vaccines, the variation of pertactin and other virulence fac-
tors of the B. pertussis strains circulating in the population
has to be monitored. It is possible that the antigenic varia-
tion is a result of vaccine-driven evolution, possibly protect-
ing the bacteria from the attacks of the host’s specific
immune response. The method described here is convenient
for large-scale screening of pertactin variation in B. pertussis
isolates. Data obtained by large-scale screening provide the
epidemiologic picture of the circulating strains. This infor-
mation may further help in vaccine formulation, which
enables more efficient protection against pertussis. It is also
possible to use a similar approach to detect the variation in
pertussis toxin gene that has been already characterized, or
in studies on genetic variation in any species. 
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